Introduction The KEYNOTE-689 clinical trial has provided a significant update on pembrolizumab’s role in treating resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Presented at the AACR 2025 Annual Meeting, this Phase 3 study (NCT03765918) evaluates neoadjuvant and adjuvant pembrolizumab alongside standard care. With promising event-free survival (EFS) results, this trial could reshape … Continue reading Pembrolizumab KEYNOTE-689 Phase 3 Trial Update for LA-HNSCC at AACR 2025